At the time of writing, Elevance Health Inc [ELV] stock is trading at $535.17, up 0.55%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ELV shares have gain 1.45% over the last week, with a monthly amount glided 0.90%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Elevance Health Inc [NYSE: ELV] stock has seen the most recent analyst activity on July 18, 2024, when BofA Securities downgraded its rating to a Neutral and also revised its price target to $530 from $646. Previously, Morgan Stanley started tracking the stock with Overweight rating on June 24, 2024, and set its price target to $643. On May 30, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $649 on the stock. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $584 on March 06, 2024. Wolfe Research downgraded its rating to a Peer Perform. Morgan Stanley upgraded its rating to Overweight for this stock on April 27, 2023, and upped its price target to $571. In a note dated April 21, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $547 on this stock.
For the past year, the stock price of Elevance Health Inc fluctuated between $431.38 and $555.35. Currently, Wall Street analysts expect the stock to reach $556.91 within the next 12 months. Elevance Health Inc [NYSE: ELV] shares were valued at $535.17 at the most recent close of the market. An investor can expect a potential return of 4.06% based on the average ELV price forecast.
Analyzing the ELV fundamentals
According to Elevance Health Inc [NYSE:ELV], the company’s sales were 171.72B for trailing twelve months, which represents an -0.06% plunge. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.4%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.17 and Total Capital is 0.98. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 529.98 points at the first support level, and at 524.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 538.79, and for the 2nd resistance point, it is at 542.40.
Ratios To Look Out For
It is important to note that Elevance Health Inc [NYSE:ELV] has a current ratio of 1.49. Considering the valuation of this stock, the price to sales ratio is 0.72, the price to book ratio is 2.94 and price to earnings (TTM) ratio is 18.76.
Transactions by insiders
Recent insider trading involved BOUDREAUX GAIL, President and CEO, that happened on Jul 22 ’24 when 34000.0 shares were sold. Director, Dixon Robert L JR completed a deal on Jul 19 ’24 to sell 305.0 shares. Meanwhile, EVP & President,Gov Health Ben Norwood Felicia F sold 6199.0 shares on Apr 24 ’24.
